GlassScriptPhysician profile
Ramon Valderrama
NPI 1922104215
$6,412.63
in general payments reported to CMS, 2019-2025
34 companies · $186 in 2025
The $186 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,134 · 2020: $132 · 2021: $1,507 · 2022: $1,049 · 2023: $1,090 · 2024: $1,315 · 2025: $186.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,592.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,591.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,725.95 | 2021-2025 | Ubrelvy, Qulipta |
| Biohaven Pharmaceuticals, INC. | $474.50 | 2021 | |
| Pfizer INC. | $433.78 | 2023-2024 | |
| Lilly USA, LLC | $391.49 | 2023-2025 | Kisunla, Amyvid, Emgality |
| Biogen, INC. | $318.24 | 2020-2024 | Leqembi |
| Abbott Laboratories | $297.89 | 2021-2025 | Infinity |
| Biohaven Pharmaceutical Holding Company LTD. | $285.00 | 2022 | |
| Avanir Pharmaceuticals, INC. | $278.87 | 2019 | |
| Amneal Pharmaceuticals LLC | $249.33 | 2019 | |
| Kyowa Kirin, INC. | $231.90 | 2023-2024 | Nourianz |
| Boston Scientific Corporation | $224.22 | 2019-2022 | |
| Corium, LLC | $202.65 | 2022-2023 | Adlarity |
| Sunovion Pharmaceuticals INC. | $166.11 | 2019 | |
| Mdd US Operations, LLC | $147.52 | 2019 | |
| Ucb, INC. | $125.01 | 2019 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ge Healthcare | $95.11 | 2023 | |
| Otsuka America Pharmaceutical, INC. | $88.02 | 2024-2025 | Rexulti |
| Amgen INC. | $81.47 | 2024-2025 | Uplizna |
| Horizon Therapeutics Plc | $72.06 | 2022-2023 | Uplizna |
| Allergan, INC. | $60.71 | 2020 | |
| Acorda Therapeutics, INC | $60.64 | 2019-2021 | |
| Neos Therapeutics, LP | $59.56 | 2023 | Adzenys Xr-Odt |
| Bausch Health US, LLC | $49.05 | 2022 | |
| Assertio Therapeutics, INC. | $40.84 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $40.07 | 2024 | Austedo Xr |
| W. L. Gore & Associates, INC. | $33.62 | 2021 | |
| Tg Therapeutics, INC. | $32.65 | 2023-2024 | |
| Adamas Pharmaceuticals, INC. | $30.21 | 2021 | |
| Genzyme Corporation | $23.80 | 2023 | |
| Eisai INC. | $20.88 | 2024 | |
| Supernus Pharmaceuticals, INC. | $19.72 | 2019 | |
| Alexion Pharmaceuticals, INC. | $19.47 | 2021 | |
| Almatica Pharma LLC | $16.67 | 2022 | |
| Catalyst Pharmaceuticals, INC. | $15.62 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ramon Valderrama listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.